Related Experiment Video
Updated: Feb 26, 2026
11:08
Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
Published on: June 22, 2012
16.7K
[News in Angiology and Hemostasis].
Pierre Fontana1, Helia Robert-Ebadi1, Marc Blondon1
1Service d'angiologie et d'hémostase, HUG, 1211 Genève 14.
Revue Medicale Suisse
|July 14, 2017
Summary
Real-world data on direct oral anticoagulants confirm pivotal study findings. New insights address thromboembolism risk, treatment of vein thrombosis, and acquired hemophilia A.
Area of Science:
- Cardiology
- Hematology
- Vascular Medicine
Background:
- Direct oral anticoagulants (DOACs) have transformed anticoagulation therapy.
- Risk stratification and management of venous thromboembolism (VTE) remain critical clinical challenges.
- Advances in hemophilia A treatment are continuously sought.
Purpose of the Study:
- To analyze real-world data on DOAC utilization and safety.
- To validate a prediction rule for VTE recurrence and anticoagulation duration.
- To review current understanding and treatment of VTE and acquired hemophilia A.
Main Methods:
- Analysis of real-world registry data for DOACs.
- Validation of a clinical prediction rule for VTE recurrence.
- Literature review and synthesis of recent data on VTE and hemophilia A.
Main Results:
- Real-world DOAC data are reassuring and align with pivotal trial results.
- A validated prediction rule aids in risk stratification for VTE recurrence.
- Updated information is provided on distal vein thrombosis treatment and VTE risk with oral contraceptives.
- A new Factor VIII concentrate for acquired hemophilia A is introduced.
Conclusions:
- Real-world evidence supports the safety and efficacy of DOACs.
- Improved risk stratification tools enhance VTE management.
- Current therapeutic strategies for VTE and acquired hemophilia A are evolving.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
14.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
14.0K
01:05Introduction to Hemostasis
15.3K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
15.3K
01:24Regulation of Angiogenesis and Blood Supply
3.8K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.8K
01:30Venous Thrombosis IV: Nursing Management
309
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
309
01:10Mechanism of Angiogenesis
7.3K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.3K